Research programme: somatropin sustained-release - Samyang
Alternative Names: hGH-PMP; hGH-SR - SamyangLatest Information Update: 11 Apr 2025
At a glance
- Originator Samyang Biopharmaceuticals Corporation; Samyang Group
- Developer Samyang Biopharmaceuticals Corporation
- Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
- Mechanism of Action Somatotropin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Growth disorders
Most Recent Events
- 11 Apr 2025 Discontinued - Preclinical for Growth disorders in South Korea (Parenteral), before April 2025
- 16 Jul 2016 No recent reports of development identified for preclinical development in Growth-disorders in South Korea (Parenteral, Controlled release)
- 20 Aug 2012 Research programme: somatropin sustained-release - Samyang is available for licensing in World as of 20 Aug 2012. http://www.samyangbiopharm.com